| Dr Christina Nicole Mack, MD | |
|
3001 Hospital Dr Dept Of, Cheverly, MD 20785-1189 | |
| (301) 618-6100 | |
| Not Available |
| Full Name | Dr Christina Nicole Mack |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 3001 Hospital Dr Dept Of, Cheverly, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730317983 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | D82318 (Maryland) | Primary |
| 207L00000X | Anesthesiology | 260119 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Md St Joseph Medical Center | Towson, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Company Llc | 4587559026 | 192 |
| University Of Maryland St Joseph Medical Group Llc | 4880846179 | 224 |
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | Anesthesia Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871548156 PECOS PAC ID: 4587559026 Enrollment ID: O20040216000401 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20040330000405 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040525000119 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | Francu One Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194972588 PECOS PAC ID: 1658437058 Enrollment ID: O20090311000028 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | University Of Maryland St Joseph Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770836785 PECOS PAC ID: 4880846179 Enrollment ID: O20121213000234 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Entity Name | Innovative Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326785395 PECOS PAC ID: 7911375829 Enrollment ID: O20221210000078 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christina Nicole Mack, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-2704 | Dr Christina Nicole Mack, MD 3001 Hospital Dr Dept Of, Cheverly, MD 20785-1189 Ph: (301) 618-6100 |
News Archive
KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.
Among 12- to 17-year-olds who have never used tobacco products, nearly half were considered receptive to tobacco marketing if they were able to recall or liked at least one advertisement, report a coalition of behavioral scientists in a new national study.
Separating vegetarian dishes on a menu can, in fact, reduce the proportion of people who choose a vegetarian option.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 3 days ago
Pamela Durning, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3001 Hospital Dr, Cheverly, MD 20785 Phone: 301-618-6100 | |
Thelma Cunningham, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3001 Hospital Dr, Cheverly, MD 20785 Phone: 301-618-6100 | |
Leeroy Mark Clarke, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3001 Hospital Dr, Cheverly, MD 20785 Phone: 301-618-6100 | |
Darryl Atwell, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3001 Hospital Dr, Cheverly, MD 20785 Phone: 301-618-6100 | |
Maria Escalera, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3001 Hospital Dr, Cheverly, MD 20785 Phone: 301-618-6100 | |
Gary J Healy, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3001 Hospital Dr, Pghc Anesthesia Associates, Cheverly, MD 20785 Phone: 301-618-6100 |